PUBLIC SUMMARY DOCUMENT

Product:SenSura Magnum High Output Two Piece System

Applicant:Coloplast Pty Ltd

Date of SPAP Meeting:25 November 2014

  1. Proposed Listing on the Stoma Appliance Scheme

The applicant, Coloplast, sought the listing of two variants to the SenSura Magnum High Output Two-Piece System (SAS code 3734M) currently listed in Subgroup 11 on the Stoma Appliance Scheme (SAS) Schedule. The products are proposed for listing at the unit price of $16.39, with a maximum monthly quantity of 10 units.

  1. Comparator

Not required.

  1. Background

The current SenSura Magnum High Output Two-Piece System (SAS code 3734M) was listed 1 July 2013 on the SAS Schedule,Coloplastis requesting to extend the current product range.

  1. Clinical Place for the Product

The proposed product provides an alternative for users requiring a high output pouch. The product is a direct substitute for other pouches currently available in Subgroup11(a).

  1. SPAP Comment

Clinical Analysis

The Panel noted that the proposed products are an extension to the existing range, and are transparent with post-op outlets.

Economic Analysis

Not undertaken.

Financial Analysis

As the proposed products are a variation to the currently listed SenSura Magnum High Output Two-Piece System (SAS code 3734M), it is therefore unlikely that there would be any budgetary impact for the SAS as a consequence of listing these variants under the conditions requested by the applicant.

  1. SPAP Recommendation

The SPAP recommended that the two variants to SenSura Magnum High Output Two-Piece System (SAS code 3734M) be listed in sub-group 11(a) of the SAS Schedule at a unit price of $16.39, with a maximum monthly quantity of 10 units.

  1. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.

  1. Applicant’s Comment

Coloplast Pty Ltd agrees with the SPAP’s recommendation contained in the Public Summary Document.

CT#3